Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2022-05-06 00:00:00 ET · period of report 2022-05-04 · accession 0000899243-22-017086 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-06 | 2022-05-04 | VRTX | Sanna Bastiano | EVP, Cell, Genetic Therapies | S - Sale | $275.09 | -36 | 41.7K | -0.1% | -$9,903 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-04 | S | D | 36 | $275.09 | 41,660 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $275.09 (range $275.00 to $275.11). (F2) Dr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |